Bristol Myers Squibb Archives

Drug Approvals

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib,

Wednesday, July 5, 2023

Drug Approvals

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.

Wednesday, March 29, 2023

Drug Approvals

Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of

Tuesday, January 31, 2023

Drug Approvals

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide

Wednesday, September 14, 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Advancing Knowledge. Enhancing Care.

Tag: Bristol Myers Squibb

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Quick Links

Follow us